152 related articles for article (PubMed ID: 33687299)
21. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid.
Naik PK; Chatterji BP; Vangapandu SN; Aneja R; Chandra R; Kanteveri S; Joshi HC
J Comput Aided Mol Des; 2011 May; 25(5):443-54. PubMed ID: 21544622
[TBL] [Abstract][Full Text] [Related]
22. Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site.
Naik PK; Santoshi S; Rai A; Joshi HC
J Mol Graph Model; 2011 Jun; 29(7):947-55. PubMed ID: 21530342
[TBL] [Abstract][Full Text] [Related]
23. A Novel Class of N-Sulfonyl and N-Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells.
Yong C; Devine SM; Gao X; Yan A; Callaghan R; Capuano B; Scammells PJ
ChemMedChem; 2019 Dec; 14(23):1968-1981. PubMed ID: 31714012
[TBL] [Abstract][Full Text] [Related]
24. Structural Basis of Noscapine Activation for Tubulin Binding.
Oliva MA; Prota AE; Rodríguez-Salarichs J; Bennani YL; Jiménez-Barbero J; Bargsten K; Canales Á; Steinmetz MO; Díaz JF
J Med Chem; 2020 Aug; 63(15):8495-8501. PubMed ID: 32657585
[TBL] [Abstract][Full Text] [Related]
25. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin).
Naik PK; Lopus M; Aneja R; Vangapandu SN; Joshi HC
J Comput Aided Mol Des; 2012 Feb; 26(2):233-47. PubMed ID: 22170255
[TBL] [Abstract][Full Text] [Related]
26. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
27. Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.
Porcù E; Sipos A; Basso G; Hamel E; Bai R; Stempfer V; Udvardy A; Bényei AC; Schmidhammer H; Antus S; Viola G
Eur J Med Chem; 2014 Sep; 84():476-90. PubMed ID: 25050880
[TBL] [Abstract][Full Text] [Related]
28. Tubulin- and ROS-dependent antiproliferative mechanism of a potent analogue of noscapine, N-propargyl noscapine.
Nambiar N; Nagireddy PKR; Pedapati R; Kantevari S; Lopus M
Life Sci; 2020 Oct; 258():118238. PubMed ID: 32791146
[TBL] [Abstract][Full Text] [Related]
29. Development of 9-(
Pragyandipta P; Naik MR; Bastia B; Naik PK
3 Biotech; 2023 Feb; 13(2):38. PubMed ID: 36636578
[TBL] [Abstract][Full Text] [Related]
30. 9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer.
Nagireddy PKR; Kumar D; Kommalapati VK; Pedapati RK; Kojja V; Tangutur AD; Kantevari S
Drug Dev Res; 2022 May; 83(3):605-614. PubMed ID: 34612529
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of noscapine analogues as microtubule-interfering agents.
Dai HL; Zheng JB; Lin M; Zheng J; Zhou FS; Dong XC; Guo L; Liu JW; Wen R
Yao Xue Xue Bao; 2012 Oct; 47(10):1347-57. PubMed ID: 23289148
[TBL] [Abstract][Full Text] [Related]
32. Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
Bennani YL; Gu W; Canales A; Díaz FJ; Eustace BK; Hoover RR; Jiménez-Barbero J; Nezami A; Wang T
J Med Chem; 2012 Mar; 55(5):1920-5. PubMed ID: 22320354
[TBL] [Abstract][Full Text] [Related]
33. 9-PAN promotes tubulin- and ROS-mediated cell death in human triple-negative breast cancer cells.
Verma P; Nagireddy PKR; Prassanawar SS; Nirmala JG; Gupta A; Kantevari S; Lopus M
J Pharm Pharmacol; 2020 Nov; 72(11):1585-1594. PubMed ID: 32959391
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel and improved antimitotic agents derived from noscapine.
Anderson JT; Ting AE; Boozer S; Brunden KR; Crumrine C; Danzig J; Dent T; Faga L; Harrington JJ; Hodnick WF; Murphy SM; Pawlowski G; Perry R; Raber A; Rundlett SE; Stricker-Krongrad A; Wang J; Bennani YL
J Med Chem; 2005 Nov; 48(23):7096-8. PubMed ID: 16279766
[TBL] [Abstract][Full Text] [Related]
35. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
36. The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents.
Debono AJ; Mistry SJ; Xie J; Muthiah D; Phillips J; Ventura S; Callaghan R; Pouton CW; Capuano B; Scammells PJ
ChemMedChem; 2014 Feb; 9(2):399-410. PubMed ID: 24339417
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel anti-cancer agents by the synthesis and cellular screening of a noscapine-based library.
Nemati F; Bischoff-Kont I; Salehi P; Nejad-Ebrahimi S; Mohebbi M; Bararjanian M; Hadian N; Hassanpour Z; Jung Y; Schaerlaekens S; Lucena-Agell D; Oliva MA; Fürst R; Nasiri HR
Bioorg Chem; 2021 Oct; 115():105135. PubMed ID: 34303039
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors.
Wang G; Liu W; Gong Z; Huang Y; Li Y; Peng Z
Bioorg Chem; 2020 Jan; 95():103565. PubMed ID: 31927336
[TBL] [Abstract][Full Text] [Related]
39. Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.
Henary M; Narayana L; Ahad S; Gundala SR; Mukkavilli R; Sharma V; Owens EA; Yadav Y; Nagaraju M; Hamelberg D; Tandon V; Panda D; Aneja R
Biochem Pharmacol; 2014 Nov; 92(2):192-205. PubMed ID: 25124704
[TBL] [Abstract][Full Text] [Related]
40. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
